Announcement • Jul 02
MindMaze Therapeutics Holding SA Enrolls First Patients in SwissNeuroRehab Study and Launches REACT-AVC Study
MindMaze Therapeutics Holding SA announced that the SwissNeuroRehab consortium has enrolled the first patients in a High-Dose, High-Intensity (HDHI) neurorehabilitation study. In parallel, MindMaze Therapeutics has launched the REACT-AVC study at Hospices Civils de Lyon, focused on early outpatient and home-based stroke rehabilitation. Building on active partnerships with approximately 100 hospitals and care facilities across Europe, MindMaze Therapeutics is now focused on extending patient access into the home. The Swiss and French studies support this goal by laying the groundwork for at-home reimbursement, enabling the Company's end-to-end solution suite to accompany patients throughout their full recovery journey, from inpatient care through outpatient rehabilitation and home. MindMaze Therapeutics' EU reimbursement strategy mirrors the model already established in the United States, where it holds CPT reimbursement codes for at-home utilization and has generated robust real-world evidence. SwissNeuroRehab is a CHF 112 million Innosuisse-backed national flagship consortium involving Swiss university hospitals, rehabilitation centers, and research, education, and industrial partners. Its mandate is to develop and validate technology-supported neurorehabilitation pathways across the continuum of care. The SwissNeuroRehab study spans six major Swiss centers and covers the full continuum of care, encompassing inpatient, outpatient, and home-based rehabilitation phases. The study is a multicenter feasibility and implementation project evaluating whether HDHI neurorehabilitation can be delivered sustainably within a continuity-of-care framework. The study is powered by MindMaze's precision neurotherapeutic platform and targets 300 minutes of active training per week, spanning a 4-6 week inpatient phase, an 8-12 week outpatient/home phase, and a follow-up at 15 months from inclusion. Recruitment is active at Lausanne University Hospital (CHUV), Institution de Lavigny, Rehaklinik Valens, Swiss Rehabilitation Sàrl, Universitätsspital Zürich, and the Lake Lucerne Institute. The study is sponsored by the CHUV, funded within the Innosuisse Flagship Program, under the project SwissNeuroRehab, and registered on ClinicalTrials.gov (NCT07427511). The SwissNeuroRehab HDHI study is part of a broader strategic European ambition. MindMaze Therapeutics is a core partner in Neurorehab4EU, a pan-European consortium spanning Switzerland, France, and Italy, designed to scale software enabled neurorehabilitation across European healthcare systems. REACT-AVC, named after the French term for stroke (Accident Vasculaire Cérébral), is the consortium's first clinical study, conducted at Hospices Civils de Lyon (HCL), one of France's academic medical centers. Aligning with SwissNeuroRehab's full-continuum design, REACT-AVC focuses on early outpatient and home-based rehabilitation for stroke patients, generating clinical and health-economic evidence to support reimbursement within the French healthcare system. Together, SwissNeuroRehab and REACT-AVC represent MindMaze Therapeutics' coordinated European evidence strategy, deployed across two healthcare systems, and designed to generate clinical and health-economic data each market's payers require.